Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "breast-cancer"

134 News Found

Pfizer Oncology hosts innovation day
News | March 01, 2024

Pfizer Oncology hosts innovation day

Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth


Novo Holdings expands portfolio in cancer diagnostics
News | January 22, 2024

Novo Holdings expands portfolio in cancer diagnostics

Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer


CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab'
News | January 17, 2024

CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab'

Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer


Briefs: Venus Remedies and Shivalik Rasayan
News | January 13, 2024

Briefs: Venus Remedies and Shivalik Rasayan

Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA


Hyderabad to host 66th All India Congress of Obstetrics and Gynaecology 2024
News | January 05, 2024

Hyderabad to host 66th All India Congress of Obstetrics and Gynaecology 2024

The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology


AstraZeneca Pharma India to launch Enhertu in January 2024
News | December 20, 2023

AstraZeneca Pharma India to launch Enhertu in January 2024

Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer


Zydus receives final USFDA approval for Cyclophosphamide Capsules USP, 25 mg and 50 mg
Drug Approval | December 17, 2023

Zydus receives final USFDA approval for Cyclophosphamide Capsules USP, 25 mg and 50 mg

Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell


Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer
Drug Approval | October 26, 2023

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients


GenWorks Health & Rotary Club partners to transform rural healthcare
Public Health | October 19, 2023

GenWorks Health & Rotary Club partners to transform rural healthcare

GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities


Venus Remedies gets marketing approval for gemcitabine and docetaxel in Serbia
News | September 21, 2023

Venus Remedies gets marketing approval for gemcitabine and docetaxel in Serbia

With this, the company has secured 511 marketing approvals for its oncology products across 66 countries